90%) and NASH (97, 10%) HCC patients were identified. Compared to VH, NASH patients were older (65) (63% vs 17%, p < 0.01), female (55% vs 19%, p < 0.01), and Hispanic (55% vs 18%, p < 0.01) while VH was seen more in Black race (41% vs 5%, p < 0.01). NASH patients had higher rates of DM (77% vs 27%, p < 0.01), hyperlipidemia (59% vs 14%, p < 0.01) and obesity (51% vs 26%, p < 0.01). CTP class, BCLC stage, rate of prior surveillance, or curative treatment (CT) rates were similar. Early stage (BCLC 0/A) NASH patients were more likely to receive CT (OR 2.0, 95% CI 1.1e3.7). There was no difference in OS between all NASH and VH patients (13 vs 16 months, p = 0.18) or after adjusting for receipt of CT (65 vs 61 months, p = 0.84). Age 65 (HR 1.4, CI 1.1e 1.8) and lack of surveillance (HR 1.49, CI 1.2e1.8) were associated with worse OS in both groups, adjusting for tumor stage, receipt of CT, and liver dysfunction. Subgroup multivariate analysis of NASH HCC associated Black race with worse OS (HR 5.9, CI 1.3e27.8). Conclusion: Though demographics differ between NASH and VH HCC patients, similar rates of surveillance, tumor stage and OS are seen. Early stage NASH patients receive more CT than VH patients but have similar OS. Black race is associated with worse OS in NASH patients when adjusted for tumor stage, liver function and receipt of CT.